cefixime has been researched along with E coli Infections in 16 studies
Cefixime: A third-generation cephalosporin antibiotic that is stable to hydrolysis by beta-lactamases.
cefixime : A third-generation cephalosporin antibiotic bearing vinyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(carboxymethoxy)imino]acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is used in the treatment of gonorrhoea, tonsilitis, pharyngitis, bronchitis, and urinary tract infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a prospective, open clinical study, 50 urological patients with acute pyelonephritis were treated with the oral cephalosporin cefixime." | 9.06 | [Effectiveness and tolerance of cefixime in the treatment of acute pyelonephritis]. ( Segal, A; Tröster, K; Weissbach, L, 1990) |
| "One hundred six patients with acute, uncomplicated lower urinary tract infections participated in a randomized study that compared cefixime (one 400-mg tablet once daily) with trimethoprim (160 mg)/sulfamethoxazole (800 mg) (one tablet every 12 hours)." | 9.06 | Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections. ( Cox, CE, 1989) |
| " The antibiotic was given at a dosage of 200 mg b." | 6.67 | [Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract]. ( Kersten, W; Müsken, H, 1990) |
| "In a prospective, open clinical study, 50 urological patients with acute pyelonephritis were treated with the oral cephalosporin cefixime." | 5.06 | [Effectiveness and tolerance of cefixime in the treatment of acute pyelonephritis]. ( Segal, A; Tröster, K; Weissbach, L, 1990) |
| "One hundred six patients with acute, uncomplicated lower urinary tract infections participated in a randomized study that compared cefixime (one 400-mg tablet once daily) with trimethoprim (160 mg)/sulfamethoxazole (800 mg) (one tablet every 12 hours)." | 5.06 | Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections. ( Cox, CE, 1989) |
| " The antibiotic was given at a dosage of 200 mg b." | 2.67 | [Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract]. ( Kersten, W; Müsken, H, 1990) |
| "Cefixime was the commonly prescribed antimicrobial (p = 0." | 1.48 | Antimicrobial misuse in pediatric urinary tract infections: recurrences and renal scarring. ( Jayaweera, JAAS; Reyes, M, 2018) |
| "Bacteriuria is associated with significant maternal and foetal risks." | 1.39 | Bacteriuria amongst pregnant women in the Buea Health District, Cameroon: prevalence, predictors, antibiotic susceptibility patterns and diagnosis. ( Atashili, J; Halle-Ekane, GE; Ikomey, GM; Mokube, MN; Ndumbe, PM, 2013) |
| "Cefixime is a cephalosporin antibiotic that is more active against Proteus spp." | 1.28 | An improved selective medium for the isolation of Escherichia coli O157. ( Chapman, PA; Jewes, L; Siddons, CA; Zadik, PM, 1991) |
| "Cefixime (CFIX) was administered orally in the treatment of 59 cases of urinary tract infection (UTI)." | 1.28 | [Treatment of urinary tract infection with cefixime]. ( Fujii, H; Fujisawa, M; Hashimoto, H; Inagaki, N; Miyata, M; Okamura, K; Sasaki, M; Yachiku, S; Yamaguchi, S; Yamauchi, K, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 5 (31.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 4 (25.00) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Tamimi, M | 1 |
| Albalawi, H | 1 |
| Shalabi, M | 1 |
| Abu-Raideh, J | 1 |
| Khasawneh, AI | 1 |
| Alhaj, F | 1 |
| Thelen, H | 3 |
| Dilworth, TJ | 3 |
| Mercier, RC | 3 |
| Jayaweera, JAAS | 1 |
| Reyes, M | 1 |
| Mokube, MN | 1 |
| Atashili, J | 1 |
| Halle-Ekane, GE | 1 |
| Ikomey, GM | 1 |
| Ndumbe, PM | 1 |
| Bocquet, N | 1 |
| Sergent Alaoui, A | 1 |
| Jais, JP | 1 |
| Gajdos, V | 1 |
| Guigonis, V | 1 |
| Lacour, B | 1 |
| Chéron, G | 1 |
| Madhi, F | 1 |
| Biscardi, S | 1 |
| Bingen, E | 1 |
| Jaby, O | 1 |
| Epaud, R | 1 |
| Cohen, R | 1 |
| Yilmaz, A | 1 |
| Gun, H | 1 |
| Yilmaz, H | 1 |
| Orth, D | 1 |
| Grif, K | 1 |
| Dierich, MP | 1 |
| Würzner, R | 1 |
| Chapman, PA | 2 |
| Siddons, CA | 2 |
| Nagar, H | 1 |
| Weiss, J | 1 |
| Kessler, A | 1 |
| Hamilton-Miller, JM | 1 |
| Zadik, PM | 1 |
| Jewes, L | 1 |
| Kersten, W | 1 |
| Müsken, H | 1 |
| Weissbach, L | 1 |
| Segal, A | 1 |
| Tröster, K | 1 |
| Cox, CE | 1 |
| Fujisawa, M | 1 |
| Sasaki, M | 1 |
| Fujii, H | 1 |
| Okamura, K | 1 |
| Miyata, M | 1 |
| Hashimoto, H | 1 |
| Yachiku, S | 1 |
| Yamauchi, K | 1 |
| Yamaguchi, S | 1 |
| Inagaki, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old. Cefixime PO 10d vs Ceftriaxone IV 4d Followed by Cefixime PO 6d. Multicenter, Randomised Trial of Equivalence.[NCT00136656] | Phase 4 | 700 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for cefixime and E coli Infections
| Article | Year |
|---|---|
Overview of cefixime use in community-acquired infections.
Topics: Cefixime; Cephalosporins; Community-Acquired Infections; Escherichia coli Infections; Female; Haemop | 2000 |
4 trials available for cefixime and E coli Infections
| Article | Year |
|---|---|
Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children.
Topics: Acute Disease; Administration, Oral; Anti-Bacterial Agents; Calcitonin; Calcitonin Gene-Related Pept | 2012 |
[Clinical experiences with cefixime in the treatment of bacterial infections of the lower respiratory tract].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; Bronchitis; Bronchopneu | 1990 |
[Effectiveness and tolerance of cefixime in the treatment of acute pyelonephritis].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Body Temperature; Cef | 1990 |
Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections.
Topics: Anti-Infective Agents, Urinary; Cefixime; Cefotaxime; Drug Administration Schedule; Escherichia coli | 1989 |
11 other studies available for cefixime and E coli Infections
| Article | Year |
|---|---|
Cefixime and cefixime-clavulanate for screening and confirmation of extended-spectrum beta-lactamases in Escherichia coli.
Topics: Adolescent; Adult; Aged; beta-Lactamases; Cefixime; Cephalosporins; Clavulanic Acid; Escherichia col | 2022 |
Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamases; Cefixime; Escherichia coli; Escheric | 2022 |
Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamases; Cefixime; Escherichia coli; Escheric | 2022 |
Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamases; Cefixime; Escherichia coli; Escheric | 2022 |
Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamases; Cefixime; Escherichia coli; Escheric | 2022 |
Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamases; Cefixime; Escherichia coli; Escheric | 2022 |
Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamases; Cefixime; Escherichia coli; Escheric | 2022 |
Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamases; Cefixime; Escherichia coli; Escheric | 2022 |
Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamases; Cefixime; Escherichia coli; Escheric | 2022 |
Examining the Combination of Cefixime and Amoxicillin/Clavulanate against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Isolates.
Topics: Amoxicillin-Potassium Clavulanate Combination; beta-Lactamases; Cefixime; Escherichia coli; Escheric | 2022 |
Antimicrobial misuse in pediatric urinary tract infections: recurrences and renal scarring.
Topics: Anti-Bacterial Agents; Biofilms; Cefixime; Child; Child, Preschool; Cicatrix; Escherichia coli; Esch | 2018 |
Bacteriuria amongst pregnant women in the Buea Health District, Cameroon: prevalence, predictors, antibiotic susceptibility patterns and diagnosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Load; Bacteriuria; Cameroon; Carboxylic Ester Hy | 2013 |
Combined relay therapy with oral cefixime and clavulanate for febrile urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli.
Topics: Administration, Oral; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefixime; Chil | 2013 |
Frequency of Escherichia coli O157:H7 in Turkish cattle.
Topics: Abattoirs; Age Factors; Animals; Cattle; Cattle Diseases; Cefixime; Culture Media; Escherichia coli | 2002 |
Variability in tellurite resistance and the ter gene cluster among Shiga toxin-producing Escherichia coli isolated from humans, animals and food.
Topics: Adhesins, Bacterial; Animals; Cattle; Cefixime; Culture Media; DNA-Binding Proteins; Drug Resistance | 2007 |
A comparison of immunomagnetic separation and direct culture for the isolation of verocytotoxin-producing Escherichia coli O157 from cases of bloody diarrhoea, non-bloody diarrhoea and asymptomatic contacts.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Bacterial Toxins; Bacteriophage Typing; Cefixime; Cef | 1996 |
Bacterial orchitis in a baby with imperforate anus.
Topics: Anus, Imperforate; Cefixime; Cefotaxime; Cephalosporins; Escherichia coli Infections; Humans; Infant | 1998 |
An improved selective medium for the isolation of Escherichia coli O157.
Topics: Anti-Infective Agents, Urinary; Bacterial Toxins; Cefixime; Cefotaxime; Culture Media; Diarrhea; Esc | 1991 |
[Treatment of urinary tract infection with cefixime].
Topics: Anti-Infective Agents, Urinary; Cefixime; Cefotaxime; Drug Evaluation; Escherichia coli Infections; | 1989 |